PDS Biotech Secures New U.S. Patent for Lead Asset PDS0101, Extending Market Protections Over 20 Years.

jueves, 22 de enero de 2026, 8:54 am ET1 min de lectura
PDSB--

PDS Biotech has announced a new US patent covering its lead asset, PDS0101, enhancing its intellectual property estate. The patent grants broad composition of method of use claims. Combined with anticipated biologics exclusivity, market protections extend over 20 years. The company is focused on transforming how the immune system targets and kills cancers.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios